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 Abstract
Background: Older guidelines recommend that fractional exhaled nitric oxide (FeNO) should be checked more than twice during the same 
session to confirm an asthma diagnosis. Recent studies show the excellent reproducibility of FeNO measurements.
Objective: We aimed to determine whether repeated FeNO measurements during the same session are necessary for asthma screening.
Methods: We retrospectively reviewed the electronic medical records of adult outpatients who visited the respiratory medicine department 
for diagnosis of asthma and assessed FeNO measurements obtained from June 2016 to July 2017.
Results: Of the 132 patients enrolled, 79 (59.8%) were diagnosed with asthma. Repeated FeNO measurements taken during the same 
session showed high reproducibility (intraclass correlation coefficient >0.9; P<.001) and a strong correlation (Pearson coefficient >0.9; 
P<.001), although reproducibility and correlation were slightly weaker in patients with low FeNO values. The value of repeated measurement 
was not significant; however, the second FeNO measurement was significantly higher than the first measurement in patients with the worst 
and best lung function. The predictive power of the first measurement of FeNO (sensitivity, 80.5%; specificity, 85.1%) was not inferior to 
the second (sensitivity, 76.6%; specificity 85.1%). The same was true of the geometric mean of the two.
Conclusion: Repeated FeNO measurement during the same session is not essential for asthma screening in cases where the first acceptable 
FeNO measurement is performed using the proper method.
Key words: Asthma. Fractional exhaled nitric oxide. Repeated measurements.
J Investig Allergol Clin Immunol 2018; Vol. 28(2): 98-105
doi: 10.18176/jiaci.0215
 Resumen
Introducción: Aunque las guías más antiguas recomiendan que el óxido nítrico exhalado (FeNO) se determine más de dos veces en la misma 
sesión para el diagnóstico de asma, algunos estudios recientes han demostrado la excelente reproducibilidad de las mediciones de FeNO.
Objetivo: Nuestro objetivo fue determinar si las mediciones repetidas de FeNO durante la misma sesión son necesarias para el cribado 
del asma.
Métodos: Revisamos retrospectivamente los registros médicos electrónicos de pacientes adultos ambulatorios que visitaron el departamento 
de neumología para confirmar un diagnóstico de asma durante los meses de junio de 2016 a julio de 2017, y se evaluaron las mediciones 
de FeNO obtenidas.
Resultados: De un total de 132 pacientes estudiados, 79 pacientes (59,8%) fueron diagnosticados con asma. Las mediciones repetidas de 
FeNO tomadas durante la misma sesión mostraron una alta reproducibilidad (coeficiente de correlación intraclase> 0,9; p <0,001) y una 
fuerte correlación (coeficiente de Pearson> 0,9; p <0,001); sin embargo, la reproducibilidad y la correlación fueron ligeramente más débiles 
en sujetos con valores bajos de FeNO. El valor de la medición repetida no fue significativamente diferente entre sí en general; sin embargo, 
la segunda medición de FeNO fue significativamente más alta que la primera medición en sujetos con valores de la función pulmonar más 
bajos y más altos. El poder predictivo de FeNO para el diagnóstico de asma medido la primera vez (sensibilidad, 80,5%; especificidad, 
85,1%) no fue inferior al medido la segunda vez (sensibilidad, 76,6%; especificidad 85,1%) o la media geométrica uniforme de los dos.
Conclusión: La medición repetida de FeNO durante la misma sesión no es esencial para el cribado del asma en los casos en que la primera 
medición de FeNO es aceptable y se realiza con el método adecuado.
Palabras clave: Asma. Óxido nítrico exhalado fraccional. Mediciones repetidas.
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Introduction
Fractional exhaled nitric oxide (FeNO) reflects eosinophilic 
airway inflammation and is easily measured. The utility 
of FeNO was recently demonstrated for the diagnosis and 
monitoring of asthma [1,2]. However, specific patient 
characteristics and environmental factors are known to 
influence FeNO levels [3-6]. In addition, to obtain a reliable 
FeNO level, the operator must be sufficiently skilled to 
maintain a constant expiratory flow rate during the test. The 
2005 American Thoracic Society (ATS)/European Respiratory 
Society (ERS) guidelines recommend performing FeNO 
measurements twice to obtain 2 values; the mean of the 
2 values should then be used to interpret the test [7]. However, 
there has been no definite evidence to support this protocol. 
The reproducibility of FeNO measurements was recently 
shown to be excellent, and it was suggested that repeated FeNO 
measurements during the same session are unnecessary [8,9]. 
The utility of multiple FeNO measurements for diagnosis of 
asthma has never been studied.
This study aimed to determine whether repeated FeNO 
measurements obtained during the same session are necessary 
for confirmation of a diagnosis of asthma.
Methods
Patients and Study Design
We retrospectively reviewed the electronic medical records 
of adult outpatients aged ≥18 years who visited the Respiratory 
Medicine Department of Gangnam Severance Hospital, Seoul, 
Korea. The patients were referred for measurement of FeNO 
between June 2016 and July 2017 to diagnose suspected 
asthma. To assess repeatability, a subset of the participants 
underwent paired FeNO measurements during the same visit. 
We examined the medical records of the patients enrolled and 
assessed baseline characteristics to define significant factors 
for FeNO level. 
FeNO Measurements
FeNO was measured using a handheld device (NObreath 
FeNO Monitor, Bedfont Scientific Ltd) during scheduled 
study visits according to ATS/ERS guidelines [7]. The device 
uses an electrochemical sensor to detect exhaled NO levels 
and provides measurements from 5 ppb to 300 ppb in whole 
numbers. We requested that all patients avoid eating, drinking, 
smoking, and performing strenuous exercise for 2 hours before 
the FeNO measurements to rule out bias. Moreover, the use 
of asthma drugs was forbidden unless the patient’s physician 
had instructed otherwise.
Patients exhaled fully while seated, then inhaled over 2 
to 3 seconds to total lung capacity through a filter, and finally 
exhaled with an upper airway pressure of 5 to 20 cmH2O. 
Two successive FeNO measurements were performed with 
an interval of 4-5 minutes between them. All patients exhaled 
against an airflow resistor for 10 seconds at a flow rate of 
50 mL/s, and the FeNO values were monitored on the screen 
of the device. Measurements were taken before performing 
spirometry. The detection limit of the NObreath device is 5 ppb.
Lung Function Test and Bronchodilator Response 
Test
Spirometry was carried out on the first study day after the 
FeNO measurements. Lung function tests were performed 
with a spirometer (Vmax, SensorMedics) in accordance with 
ATS/ERS recommendations [10]. Forced expiratory volume 
in 1 s (FEV1), forced vital capacity (FVC), and the FEV1/FVC 
ratio were obtained from the best reproducible forced expiratory 
maneuvers. A significant improvement in lung function resulting 
from bronchodilator use was defined as an improvement in 
prebronchodilator FEV1 of ≥12% and 200 mL after administration 
of salbutamol (200 μg).
Methacholine Challenge Test
The methacholine challenge test was carried out using the 
standard 5-breath dosimeter method recommended by the ATS 
[11]. Methacholine dilutions of 1, 4, 8, and 16 mg/mL were 
used. Spirometry was performed 30 seconds and 90 seconds 
after each inhalation. The test was finished when the FEV1 
value decreased by more than 20% from baseline. Positivity 
was defined as a provocative concentration <16 mg/mL that 
resulted in a 20% decrease in FEV1. 
Asthma Diagnosis
Asthma was diagnosed by clinicians based on the 
symptoms, physical examination, and the results of the 
bronchodilator test and methacholine test in all patients 
according to the Global Initiative for Asthma standard [12]. 
Definition of a Large Gap and Positivity in FeNO 
Measurements
The upper quartile of patients with a larger gap between 
the first and second individual measurement values formed the 
large gap group. Moreover, a large gap was defined as a >17.5% 
difference in FeNO values between the 2 measurements. 
Although there are some concerns about the cut-off value for 
FeNO, we adopted 30 ppb based on findings from previous 
studies, including a Korean study [13,14].
Statistics
All data analyses were performed using SPSS (SPSS 
Inc). As the FeNO values appeared to be log-normally 
distributed, we used the geometric mean. The chi-square test 
and t test were used to assess differences in characteristics 
between patients with and without a large gap. The intraclass 
correlation coefficient (ICC) and Pearson correlation were 
used to assess the reproducibility and correlation between 
the first and second FeNO measurements. The significance 
of the difference in FeNO values between the first and second 
measurements was assessed using the paired t test. Agreement 
between FeNO positivity and a diagnosis of asthma diagnosis 
was calculated. Univariate and multivariate regression 
analyses showed that sex, age, height, weight, body mass 
index (BMI), pulmonary function variables, and asthma 
history were significantly associated with FeNO level. After 
adjustment for significant factors (absolute FVC and FEV1), 
the ability to predict asthma was based on a receiver operating 
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with a large gap (39.4%; P=.005). Patients with large gaps 
showed significantly lower FeNO values than those without 
large gaps (Table 1).
Reliability, Correlation, and Comparison of FeNO 
Measurements
In general, repeated FeNO measurements showed high 
reproducibility (ICC>0.9; P<.001) and strong correlations 
(Pearson coefficient >0.9; P<.001); however, in patients with 
low FeNO levels (<52.8 ppb), the values for reliability and 
correlation were slightly weaker (ICC, 0.772-0.886; Pearson 
coefficient, 0.681-0.774) (Table 2; Figure, A).
The first FeNO levels measured (32.5 [2.3] ppb) were 
not significantly different from the second FeNO levels (33.4 
[2.3] ppb) (Figure, B). However, the second values were 
significantly higher than the first values in patients with the 
poorest lung function (44.36 ppb vs 40.60 ppb in patients with 
the lowest FVC values, P=.024) (Table 2). This trend was also 
observed in patients with the best lung function (30.74 ppb vs 
28.79 ppb in patients with the highest FVC values, P=.004; 
34.34 ppb vs 32.50 ppb in patients with the highest FEV1 
values, P=.014).
Predictability of FeNO Measurements for Asthma 
Diagnosis Using the Agreement Rate
When FeNO positivity was defined as ≥30 ppb, the 
predictive power of the FeNO measurement for asthma was 
excellent. Overall, the first measured FeNO value was not 
inferior to the second measurement for prediction of asthma 
in all subgroups (total agreement rate, 79.5% vs 78.0%). 
Moreover, the total agreement rate for asthma using the first 
value was not inferior to that using the numerical mean of the 2 
characteristic analysis to obtain the area under the curve, 
the sensitivity and specificity of the first and second FeNO 
measurements, the geometric mean, the larger of the 2 values, 
and the smaller of the 2 values. A P value less than .05 was 
considered statistically significant.
Ethics
This study was exempt from approval by the Institutional 
Review Board of the Gangnam Severance Hospital, Yonsei 
University Health System.
Results
Clinical Characteristics of the Patients
 Of the 132 patients enrolled (mean age, 42.8 [16.0] 
years; men, 50.0%), 79 (59.8%) were diagnosed with asthma. 
The geometric mean values of the first and second FeNO 
measurements were 32.5 ppb and 33.4 ppb, respectively; 
there was no statistically significant difference between the 2 
values (Table 1). 
Determinants of a Large Gap in FeNO 
Measurements
 When we used 17.5% as the threshold for a large gap 
between FeNO measurements, 33 patients (25.0%) were 
classified as belonging to the large gap group. Sex, age, height, 
weight, and lung function were not significantly different 
between patients with and without a large gap. Patients with 
a large gap had significantly higher BMI values than those 
without a large gap (P=.015). Asthma was significantly more 
prevalent in patients without a large gap (66.7%) than in those 
Table 1. Clinical Characteristics, Lung Function Test, and Geometric Mean of FeNO According to Group  
Variables Total Patients Without Large Gapa Patients With Large Gapa P Value 
  (N=132) (n=99) (n=33)
Sex (Male) 50.0% 51.5% 45.5% .546
Age, y 42.8 (16.0) 41.9 (15.2) 45.5 (18.2) .307
Height, cm 165.7 (9.2) 166.5 (9.4) 163.1 (7.9) .079
Weight, kg 66.6 (13.1) 66.1 (14.0) 67.9 (10.1) .535
BMI, kg/m2 24.2 (3.7) 23.7 (3.5) 25.6 (3.9) .015b
Absolute FVC, L 3.8 (1.0) 3.9 (1.0) 3.6 (1.0) .094
Predicted FVC, % 97.3 (13.0) 97.9 (13.1) 95.7 (12.8) .419
Absolute FEV1, L 3.0 (0.8) 3.0 (0.8) 2.8 (0.9) .226
Predicted FEV1, % 99.1 (16.3) 99.1 (16.2) 99.1 (16.8) .998
Asthma 59.8% 66.7% 39.4% .005b
Geometric mean of FeNO, ppb     
 First measurement  32.5 (2.3) 37.7 (2.4) 20.9 (1.8) <.001b 
 Second measurement  33.4 (2.3) 38.5 (2.4) 21.8 (1.8) .001b
Abbreviations: BMI, body mass index; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
aA large gap was defined as a >17.5% difference in FeNO between the first and second measurements.
bSignificant factors (independent samples t-test).
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Figure. Correlation (A) and comparison (B) between the first and second FeNO measurements.
Table 2. Reliability, Correlation, and Comparison of FeNO Measurements  
 Variables Patients,        Intraclass Correlation      Pearson correlation  Paired t Test
  No. Coefficient P Value Coefficient P Value First  Second P Value 
       Measurement Measurement 
Sex 
 Male 66 0.988 <.001 0.977 <.001 33.28 33.62 .584 
 Female 66 0.989 <.001 0.979 <.001 31.83 33.20 .095
Age 
 <65  115 0.991 <.001 0.983 <.001 32.26 32.83 .236 
 ≥65 17 0.929 <.001 0.952 <.001 34.56 37.61 .233
BMI 
 <18.5  6 >0.999 <.001 0.999 <.001 40.17 39.75 .428 
 18.5-23 40 0.986 <.001 0.973 <.001 28.17 29.32 .222 
 23-25 29 0.989 <.001 0.979 <.001 34.85 36.34 .210 
 >25 40 0.983 <.001 0.967 <.001 29.84 29.86 .984
FVC 
 <25% (<3.12 L) 31 0.989 <.001 0.980 <.001 40.60 44.36 .024a 
 25-50% (3.12-3.71 L) 32 0.988 <.001 0.979 <.001 31.11 30.42 .507 
 20-75% (3.71-4.65 L) 30 0.988 <.001 0.976 <.001 32.59 32.66 .944 
 >75% (>4.65 L) 31 0.995 <.001 0.991 <.001 28.79 30.74 .004a
FEV1 
 <25% (<2.46 L) 31 0.989 <.001 0.979 <.001 48.59 52.00 .088 
 25-50% (2.46-3.00 L) 33 0.978 <.001 0.958 <.001 30.77 31.47 .466 
 20-75% (3.00-3.58 L) 29 0.989 <.001 0.978 <.001 23.97 23.60 .642 
 >75% (>3.58 L) 31 0.995 <.001 0.991 <.001 32.50 34.34 .014a
FeNO 
 <25% (<18.25) 33 0.866 <.001 0.774 <.001 11.76 12.67 .117b 
 25-50% (18.25-32.00) 34 0.772 <.001 0.715 <.001 24.40 24.74 .613b 
 50-75% (32.00-52.75) 32 0.780 <.001 0.681 <.001 40.04 39.77 .783b 
 >75% (>52.75) 33 0.991 <.001 0.983 <.001 99.14 101.38 .204
Total 132 0.989 <.001 0.978 <.001 32.55 33.40 .094
Abbreviations: BMI, body mass index; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
aP value <.05 obtained by paired t test. 
bSlightly decreased reliability and correlation of FeNO between first and second measurements.
Pearson coefficient, 0.978
P<.001
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values, the larger of the first and second values, or the smaller 
of the first and second values (Table 3).
Significant Determinants of the FeNO Value 
In the univariate linear regression analysis, sex, height, 
weight, and BMI were not significantly associated with 
the FeNO value. Age showed borderline significance 
(P=.050). The absolute FVC, predicted FVC, and absolute 
FEV1 were significant factors for FeNO. The multivariate 
linear regression analysis showed that absolute FVC and 
absolute FEV1 were significantly associated with FeNO 
levels (Table 4).
Table 4. Significant Factors in the Determination of the FeNO Value  
  Univariate Analysis   Multivariate Analysis 
 Coefficients Standard Error P Value Coefficients Standard Error P Value 
Gender –0.045 0.147 .763   
Age 0.009 0.005 .050 0.003 0.006 .637
Height –0.004 0.008 .596   
Weight –0.006 0.006 .284   
BMI –0.021 0.021 .311   
Absolute FVC –0.195a 0.092a .035a 0.361a 0.174a .041a
Predicted FVC –0.009 0.005 .045 –0.001 0.007 .846
Absolute FEV1 –12.740a 5.669a .026a –0.532a 0.219a .017a
Predicted FEV1 <0.001 0.006 .996   
Abbreviations: BMI, body mass index; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity. 
aSignificant factors for first FeNO measurement by multivariate linear regression analysis.
Table 3. Agreement Rate Between FeNO Positivity (≥30 ppb) and Asthma  
Variables First Second Numerical Larger one Smaller one 
  Measurement Measurement Mean of  Selection Selection 
    2 Above Between 2 Above  Between 2 Above 
FVC 
 <25% (<3.12 L) 87.1%a 83.9% 87.1%a 83.9% 87.1%a
 25-50% (3.12-3.71 L) 84.4%a 75.0% 78.1% 81.3% 78.1%
 20-75% (3.71-4.65 L) 70.0% 73.3%a 70.0% 73.3%a 70.0%
 >75% (>4.65 L) 77.4%a 77.4%a 77.4%a 77.4%a 77.4%a
FEV1 
 <25% (<2.46 L) 90.3%a 87.1% 90.3%a 87.1% 90.3%a
 25-50% (2.46-3.00 L) 75.8%a 69.7% 69.7% 75.8%a 69.7%
 20-75% (3.00-3.58 L) 69.0%a 69.0%a 69.0%a 69.0%a 69.0%a
 >75% (>3.58 L) 83.9%a 83.9%a 83.9%a 83.9%a 83.9%a
FeNO, ppb 
 <25% (<18.25) 70.0%a 70.0%a 70.0%a 70.0%a 70.0%a
 25-50% (18.25-32.00) 70.6%a 67.6% 70.6%a 67.6% 70.6%a
 50-75% (32.00-52.75) 81.3%a 78.1% 75.0% 81.3%a 78.1%
 >75% (> 52.75) 97.0%a 97.0%a 97.0%a 97.0%a 97.0%a
Total 79.5%a 78.0% 78.0% 78.8% 78.8%
Abbreviations: FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
aHighest agreement rate in the subgroup.
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Predictive Power of FeNO Measurements for 
Diagnosis of Asthma Using a Multiple Regression 
Analysis
After adjustment for lung function (FVC and FEV1, based 
on the results of Table 4), the first FeNO value measured 
(AUC, 0.859; 95%CI, 0.794-0.924; P<.001; sensitivity, 
80.5%; specificity, 85.1% with a cut-off of 30.0 ppb) was not 
significantly inferior to the second measured value (AUC, 
0.850; 95%CI, 0.785-0.916; P<.001; sensitivity, 76.6%; 
specificity 85.1% with a cut-off of 29.0 ppb) (comparison of the 
ROC curves between the first FeNO value and second FeNO 
value, P=.694), the geometric mean of the 2 measurements 
(AUC, 0.856; 95%CI, 0.792-0.922; P<.001; sensitivity, 81.8%; 
specificity, 83.0%) (comparison of ROC curves between first 
FeNO value and geometric mean FeNO value, P=.923), the 
larger of the 2 values (AUC, 0.857; 95%CI, 0.793-0.922; 
P<.001; sensitivity, 79.2%; specificity, 85.1%) (comparison 
of ROC curves between first FeNO value and larger one, 
P>.999), or the smaller of the 2 values (AUC, 0.859; 95%CI, 
0.795-0.923; P<.001; sensitivity, 81.8%; specificity, 80.9%) 
(comparison of ROC curves between the first FeNO value and 
the smaller one, P=.848) (Table 5). 
Discussion
We demonstrated that repeated FeNO measurements during 
the same session are not essential for diagnosis of asthma. 
The FeNO value was highly reproducible. In addition, the 
predictive value of the first FeNO measurement for asthma 
was not inferior to that measured the second time [15], the 
mean of the 2 values, the larger value, or the smaller value. 
Various institutions currently use the protocol recommended 
in the 2005 ATS/ERS guidelines, which state that the FeNO 
level should be measured twice and the mean value should be 
applied [7]. However, this recommendation is not supported 
by sufficient scientific evidence. Recent studies showed 
the excellent reproducibility and repeatability of FeNO 
measurements [8,9]. However, whether an asthma diagnosis 
can be made with only 1 FeNO measurement has not been 
studied. We suggest that the time and effort required to repeat 
the FeNO measurement could be saved, because a single FeNO 
measurement is sufficient to diagnose asthma.
Table 5. Predictive Power of FeNO Measurements for Asthma Diagnosis Using a Multiple Regression Analysisa  
Variables AUC 95% CI P Value Sensitivity Specificity 
First measurement 0.859a 0.794-0.924a <.001a 80.5%a 85.1%a
Second measurement 0.850 0.785-0.916 <.001 76.6% 83.0%
Geometric mean of the previous two 0.856 0.792-0.922 <.001 81.8% 83.0%
Larger of the previous two 0.857 0.793-0.922 <.001 79.2% 85.1%
Smaller of the previous two 0.859 0.795-0.923 <.001 81.8% 80.9%
Abbreviations: AUC, area under the curve; FeNO, fractional exhaled nitric oxide. 
aAll data are obtained by logistic regression after adjustment with absolute FVC and FEV1.
aBest results among the variables.
Although we proved the excellent predictive value of a 
single FeNO measurement for diagnosis of asthma, some 
patients showed a significant gap in FeNO levels between the 
first and second measurements. Patients with normal-to-low 
FeNO values (in the bottom 75%) showed modest agreement 
between the first and second FeNO values measured. The 
groups with the best lung function (in the top 25%) and worst 
lung function (in the bottom 25%) showed significantly 
higher FeNO values for the second measurement than for the 
first measurement. Therefore, we need to pay attention when 
measuring FeNO levels in these subgroups, where more than 
1 measurement of the FeNO level may be necessary to obtain 
a definitive value. However, repeating the measurement may 
not affect the diagnosis of asthma.
 Lung function played a significant role in the measurement 
of FeNO, whereas age, sex, and height did not. Several studies 
have demonstrated that age, sex, height, atopy, smoking 
status, and lung function can influence the level of FeNO [16]; 
however, no consensus has been reached [3-6,10,13,17,18]. 
We attempted to establish significant associations between 
these factors. Given that our study included a relatively small 
number of patients compared with previous studies, we could 
not be sure that age, sex, and height were not significantly 
associated. We reconfirmed that lung function was negatively 
correlated with FeNO values, consistent with previous data 
from a group in Korea [10]. A possible explanation for 
this finding could be that patients with severe eosinophilic 
inflammation might have high levels of FeNO and poor lung 
function [19].
 Asthma is a chronic inflammatory airway disease that 
can be diagnosed and monitored using various tests [20]. 
The classic tests include lung function, a questionnaire, and 
induced sputum. Data were recently reported for FeNO and 
periostin, and interest in potential biomarkers such as IgE, 
ykl-40, and CD93 has grown [21-24]. In the clinic, the FeNO 
level is easily measured before the performance of the lung 
function test. The utility of FeNO values has been widely 
demonstrated [25,26]; therefore, FeNO will be used more 
extensively in the future. Our study showed that repeated 
measurements of FeNO were unnecessary; consequently, the 
convenience and ease of a single FeNO measurement will 
enhance the utility of this approach.
 Our study is subject to a series of limitations. First, it 
was performed at a single institution with a small number of 
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patients. Our results should be confirmed in a larger study. 
Second, despite having a highly skilled and well-trained 
practitioner (which ensures excellent reproducibility), we 
are unsure whether a single FeNO measurement would be 
sufficient at institutions without skilled trainers. Third, we 
should interpret the results carefully, because we might 
have included patients with noneosinophilic asthma. Lastly, 
atopy, which is known to be significantly associated with 
FeNO level, was not included in the analysis because of 
missing data.
 In conclusion, a single FeNO measurement was sufficient 
for asthma screening in cases where the first acceptable 
FeNO measurement was made using the appropriate method. 
A second measurement would be helpful in cases where the 
first acceptable measurement is much lower or higher than 
the clinician expected and in cases where lung function is 
extremely good or poor. 
Funding
The authors declare that no funding was received for the 
present study.
Conflicts of Interest 
The authors declare that they have no conflicts of interest.
References
 1. Kim HB, Eckel SP, Kim JH, Gilliland FD. Exhaled NO: 
Determinants and Clinical Application in Children With 
Allergic Airway Disease. Allergy Asthma Immunol Res. 
2016;8:12-21.
 2. Feng JX, Lin Y, Lin J, He SS, Chen MF, Wu XM, et al. Relationship 
between Fractional Exhaled Nitric Oxide Level and Efficacy of 
Inhaled Corticosteroid in Asthma-COPD Overlap Syndrome 
Patients with Different Disease Severity. J Korean Med Sci. 
2017;32:439-47.
 3. Olin AC, Rosengren A, Thelle DS, Lissner L, Bake B, Toren K. 
Height, age, and atopy are associated with fraction of exhaled 
nitric oxide in a large adult general population sample. Chest. 
2006;130:1319-25.
 4. Kovesi T, Kulka R, Dales R. Exhaled nitric oxide concentration is 
affected by age, height, and race in healthy 9- to 12-year-old 
children. Chest. 2008;133:169-75.
 5. Levesque MC, Hauswirth DW, Mervin-Blake S, Fernandez CA, 
Patch KB, Alexander KM, et al. Determinants of exhaled nitric 
oxide levels in healthy, nonsmoking African American adults. J 
Allergy Clin Immunol. 2008;121:396-402 e3.
 6. Dressel H, de la Motte D, Reichert J, Ochmann U, Petru R, 
Angerer P, et al. Exhaled nitric oxide: independent effects of 
atopy, smoking, respiratory tract infection, gender and height. 
Respir Med. 2008;102:962-9.
 7. American Thoracic Society, European Respiratory Society. ATS/
ERS recommendations for standardized procedures for the 
online and offline measurement of exhaled lower respiratory 
nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care 
Med. 2005;171:912-30.
 8. Kapande KM, McConaghy LA, Douglas I, McKenna S, Hughes 
JL, McCance DR, et al. Comparative repeatability of two 
handheld fractional exhaled nitric oxide monitors. Pediatr 
Pulmonol. 2012;47:546-50.
 9. Bohadana A, Michaely JP, Teculescu D, Wild P. Reproducibility 
of exhaled nitric oxide in smokers and non-smokers: relevance 
for longitudinal studies. BMC Pulm Med. 2008;8:4.
 10. Jo EJ, Song WJ, Kim TW, Park HW, Chang YS, Kim TB, et al. 
Reference ranges and determinant factors for exhaled nitric 
oxide in a healthy korean elderly population. Allergy Asthma 
Immunol Res. 2014;6:504-10.
 11. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson 
JL, Irvin CG, et al. Guidelines for methacholine and exercise 
challenge testing-1999. This official statement of the American 
Thoracic Society was adopted by the ATS Board of Directors, 
July 1999. Am J Respir Crit Care Med. 2000;161:309-29.
 12. GINA report, Global Strategy for Asthma Management and 
Prevention. http://www.ginasthma.com/guidelineitem.asp? 
112& 121& intId1561. Accessed September 27, 2017.
 13. Kim SH, Kim TH, Sohn JW, Yoon HJ, Shin DH, Park SS. Reference 
values and determinants of exhaled nitric oxide in healthy 
Korean adults. J Asthma. 2010;47:563-7.
 14. Chatkin JM, Ansarin K, Silkoff PE, McClean P, Gutierrez C, 
Zamel N et al. Exhaled nitric oxide as a noninvasive assessment 
of chronic cough. Am J Respir Crit Care Med. 1999;159:1810-
3.
 15. Olaguibel JM, Parra A, Alvarez MJ, Quirce S, Lopez R. 
Measurements of fractional exhaled nitric oxide with 2 
portable electrochemical sensors: a comparative study. J 
Investig Allergol Clin Immunol. 2011;21:322-3.
 16. Alvarez-Puebla MJ, Olaguibel Rivera JM, Almudevar E, 
Echegoyen AA, de Esteban Chocarro B, Cambra K. Cutoff 
point for exhaled nitric oxide corresponding to 3% sputum 
eosinophils. J Investig Allergol Clin Immunol. 2015;25:107-
11.
 17. Olivieri M, Talamini G, Corradi M, Perbellini L, Mutti A, Tantucci 
C, et al. Reference values for exhaled nitric oxide (reveno) 
study. Respir Res. 2006;7:94.
 18. Travers J, Marsh S, Aldington S, Williams M, Shirtcliffe P, 
Pritchard A, et al. Reference ranges for exhaled nitric oxide 
derived from a random community survey of adults. Am J 
Respir Crit Care Med. 2007;176:238-42.
 19. Amelink M, de Groot JC, de Nijs SB, Lutter R, Zwinderman 
AH, Sterk PJ, et al. Severe adult-onset asthma: A distinct 
phenotype. J Allergy Clin Immunol. 2013;132:336-41.
 20. Kim DK, Park YB, Oh YM, Jung KS, Yoo JH, Yoo KH, et al. 
Steering, Scientific Committee of Asthma Study G, Guideline 
Control Committee in The Korean Academy of T, Respiratory D. 
Korean Asthma Guideline 2014: Summary of Major Updates 
to the Korean Asthma Guideline 2014. Tuberc Respir Dis 
(Seoul). 2016;79:111-20.
 21. Park HJ, Han H, Lee SC, Son YW, Sim DW, Park KH, et al. 
Soluble CD93 in Serum as a Marker of Allergic Inflammation. 
Yonsei Med J. 2017;58:598-603.
 22. Song WJ, Sintobin I, Sohn KH, Kang MG, Park HK, Jo EJ, et 
al. Staphylococcal enterotoxin IgE sensitization in late-onset 
severe eosinophilic asthma in the elderly. Clin Exp Allergy. 
2016;46:411-21.
 23. Lee JH, Park KH, Park JW, Hong CS. YKL-40 in induced sputum 
after allergen bronchial provocation in atopic asthma. J 
Investig Allergol Clin Immunol. 2012;22:501-7.
104
Utility of Repeated FeNO Measurements
J Investig Allergol Clin Immunol 2018; Vol. 28(2): 98-105© 2018 Esmon Publicidad
doi: 10.18176/jiaci.0215
 24. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, 
et al. Bronchoscopic Exploratory Research Study of Biomarkers 
in Corticosteroid-refractory Asthma Study G. Periostin is a 
systemic biomarker of eosinophilic airway inflammation in 
asthmatic patients. J Allergy Clin Immunol. 2012;130:647-54 
e10.
 25. Silkoff PE, Lent AM, Busacker AA, Katial RK, Balzar S, Strand M, 
et al. Exhaled nitric oxide identifies the persistent eosinophilic 
phenotype in severe refractory asthma. J Allergy Clin Immunol. 
2005;116:1249-55.
 26. Perez-de-Llano LA, Carballada F, Castro Anon O, Pizarro 
M, Golpe R, Baloira A, et al. Exhaled nitric oxide predicts 
control in patients with difficult-to-treat asthma. Eur Respir J. 
2010;35:1221-7.
 Manuscript received October 26, 2017; accepted for 
publication November 27, 2017.
  Hye Jung Park 
Department of Internal Medicine
Gangnam Severance Hospital, Yonsei University College 
of Medicine
211, Eonju-ro, Gangnam-gu, Seoul, 
Republic of Korea, 06273
E-mail: craft7820@yuhs.ac
105
